Bayer / Manufacturers of America / Pfizer / Merck / Lehman Brothers / Pharmaceutical Research / National Public Radio / /
Country
United States / /
Currency
USD / /
Event
FDA Phase / /
Facility
PRIME Institute / Albert Einstein College of Medicine / University of Minnesota / Tufts University / / /
IndustryTerm
quickest pharmaceutical / pharmaceutical experts / clean and safe energy sources / pharmaceutical industry / campaign finance reform / pharmaceutical economics / pharmaceutical compound / policy makers / direct-to-consumer advertising / lobby / drug industry advertising budgets / research / chemical entities / pharmaceutical industry experts / /
MedicalCondition
diseases / /
Movie
Professor / /
Organization
National Institute of Health / Food and Drug Administration / Supreme Court / Department of Epidemiology and Social Medicine / office of Technology Assessment / NIH office of Science Policy / Tufts University / Using government / U.S. Securities and Exchange Commission / General Accounting Office / Tufts Center / Public Citizen Public Citizen / Congress / office of Technology Assessment Report / Albert Einstein College of Medicine / PRIME Institute / University of Minnesota / Tufts Center for the Study of Drug Development / Call Public Citizen’s Publication Office / /
Person
Stephen W. Schondelmeyer / Alan Holmer / Everett Intern Coco Jervis / Sidney M. Wolfe / Larry D. Sasich / Michael Surrusco / Bob Young / Joseph DiMasi / Ralph Nader / Peter S. Arno / Frank Clemente / / /
Position
economist / president / Researcher / Watch Director / Director Research / major U.S. drug companies and their Washington / D.C. lobby group / Professor of Pharmaceutical Economics and Director / Major U.S. drug companies / Professor / director / CONTENTS Executive / /
Product
Drug / /
ProvinceOrState
Minnesota / /
RadioProgram
Talk of the Nation / /
Technology
combinatorial chemistry / genomics / Drug Development / /
Rx R&D Myths: The Case Against The Drug Industry’s R&D “Scare Card” Congress Watch July 2001